Influence of quercetin on diabetes-induced alteration in CYP3A activity and bioavailability of pioglitazone in rats

American Journal of Infectious Diseases

Volumn 5, Issue 2, 2009, Pages 118-125

  Umathe, Sudhir Niranjan ^a   Dixit, Pankaj Vinod ^a   Vaghasiya, Jignesh Manubhai ^a   Jain, Nishant Sudhir ^b  

^a RTM NAGPUR UNIVERSITY   (India)

^b JL Chaturvedi College of Pharmacy   (India)

Author keywords

Alloxan; Diabetic gastroparesis; Erythromycin N demethylase; Herbal medicine

Indexed keywords

ALLOXAN; CYTOCHROME P450 3A; PIOGLITAZONE; QUERCETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; GENE ACTIVITY; INTESTINE TRANSIT TIME; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; STOMACH EMPTYING; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

EID: 70349662024     PISSN: 15536203     EISSN: None     Source Type: Journal    
DOI: 10.3844/ajidsp.2009.118.125     Document Type: Article

References (27)

1. Jung, M., M. Park, H.C. Lee, Y.H. Kang, E.S. Kang and S.K. Kim, 2006. Antidiabetic agents from medicinal plants. Curr. Med. Chem., 13: 1203-1218. http://www.bentham.org/cmc/contabs/cmc13-10.htm#8
2. Wheaton, A.G., H.M. Blanck, Z. Gizlice and M. Reyes, 2005. Medicinal herb use in a population-based survey of adults: Prevalence and frequency of use, reasons for use and use among their children. Ann. Epidemiol., 15: 678-685. DOI: 10.1016/J.ANNEPIDEM.2004.09.002
3. Bonnefont-Rousselot, D., 2004. The role of antioxidant micronutrients in the prevention of diabetic complications. Treat. Endocrinol., 3: 41-52. http://www.ingentaconnect.com/content/adis/end/2004/00000003/00000001/ art00005
4. Fujita, K., M. Hidaka, N. Takamura, K. Yamasaki, T. Iwakiri, M. Okumura, H. Kodama, M. Yamaquchi, T. Ikenoue and K. Arimori, K., 2003. Inhibitory effects of citrus fruits on cytochrome P450 3A (CYP3A) activity in humans. Biol. Pharm. Bull., 26: 1371-1373. DOI: 10.1248/bpb.26.1371
5. Izzo, A.A., 2005. Herb-drug interactions: An overview of the clinical evidence. Fundam. Clin. Pharmacol., 19: 1-16. http://www.ncbi.nlm.nih.gov/pubmed/15660956
6. Pal, D. and A.K. Mitra, 2006. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci., 78: 2131-2145. DOI: 10.1016/J.LFS.2005.12.010
7. Eckland, D.A. and M. Danhof, 2000. Clinical pharmacokinetics of pioglitazone. Exp. Clin. Endocrinol. Diab., 108: S234-242. http://direct.bl.uk/bld/PlaceOrder.do?UIN=087321393&ETOC= RN&from=searchengine
8. Weaver, M.L., B.A. Orwig, Rodriguez, E.D. Graham, J.A. Chin, M.J. Shapiro, J.F. McLeod and J.B. Mangold, 2001. Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab. Dispos., 29: 415-421. http://dmd.aspetjournals.org/cgi/content/full/29/4/415
9. Umathe, S.N., P.V. Dixit, V. Kumar, K.U. Bansod and M.M. Wanjari, 2008. Quercetin pretreatment increases the bioavailability of pioglitazone in rats: Involvement of CYP3A inhibition. Biochem. Pharmacol., 75: 1670-1676. DOI: 10.1016/j.bcp.2008.01.010
10. Borbas, T., B. Benko, B. Dalmadi, I. Szabo and K. Tihanyi, 2006. Insulin in flavin-containing monooxygenase regulation. Flavin-containing monooxygenase and cytochrome P450 activities in experimental diabetes. Eur. J. Pharm. Sci., 28: 51-58. DOI: 10.1016/J.EJPS.2005.12.011
11. Yamada, Y., H. Matsuo, S. Watanabe, K. Kato, K. Yajima, T. Hibino, K. Yokoi, S. Ichihara, N. Metoki, H. Yoshida, K. Satoh and Y. Nozawa, 2007. Association of a polymorphism of CYP3A4 with type 2 diabetes mellitus. Int. J. Mol. Med., 20: 703-707. http://www.ncbi.nlm.nih.gov/pubmed/ 17912464
12. Horowitz, M., M. Edelbroek, R. Fraser, A. Maddox and J. Wishart, 1991. Disordered gastric motor function in diabetes mellitus. Recent insights into prevalence, pathophysiology, clinical relevance and treatment. Scand. J. Gastroenterol., 26: 673-684. DOI: 10.3109/00365529108998583
13. Hermann, R., H.J. Wildgrube, P. Ruus, G. Niebch, H. Nowak and C.H. Gleiter, 1998. Gastric emptying in patients with insulin dependent diabetes mellitus and bioavailability of thioctic acid-enantiomers. Eur. J. Pharm. Sci., 6: 27-37. DOI: 10.1016/S0928-0987(97)00065-1
14. Fraser, R.J., M. Horowitz, A.F. Maddox, P.E. Harding, B.E. Chatterton and J. Dent, 1990. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 33: 675-680. DOI: 10.1007/BF00400569
15. Rerup, C.C., 1970. Drugs producing diabetes through damage of insulin secreting cells. Pharmacol. Rev., 22: 485-518. http://pharmrev.aspetjournals.org/content/vol22/issue4/
16. Vessal, M., M. Hemmati and M. Vasei, 2003. Antidiabetic effects of quercetin in streptozotocin-induced diabetic rats. Comp. Biochem. Physiol. C. Toxicol. Pharmacol., 135C: 357-364. DOI: 10.1016/ S1532-0456(03)00140-6
17. Nuraliev, Iu.N. and G.A. Avezov, 1992. The efficacy of quercetin in alloxan diabetes. Eksp. Klin. Farmakol., 55: 42-44. http://www.ncbi.nlm.nih.gov/sites/entrez
18. Xie, W., D. Xing, Y. Zhao, H. Su, Z. Meng, Y. Chen and L. Du, 2005. A new tactic to treat postprandial hyperlipidemia in diabetic rats with gastroparesis by improving gastrointestinal transit. Eur. J. Pharmacol., 510: 113-120. DOI: 10.1016/J.EJPHAR.2005.01.019
19. Umathe, S.N., N.I. Kochar, N.S. Jain and P.V. Dixit, 2009. Gastrointestinal dysfunction in diabetic rats relates with a decline in tissue l-arginine content and consequent low levels of nitric oxide. Nitric Oxide, 20: 129-133. DOI: 10.1016/j.niox.2008.10.007
20. Fluttert, M., S. Dalm and M.S. Oitzl, 2000. A refined method for sequential blood sample by tail incision. Lab. Anim., 34: 372-378. DOI: 10.1258/002367700780387714.
21. Gillies, P.S. and C.J. Dunn, 2000. Pioglitazone. Drugs, 60: 333-343. http://direct.bl.uk/bld/PlaceOrder.do?UIN=083253770&ETOC= RN&from=searchengine
22. Belcher, G. And D.R. Matthews, 2000. Safety and tolerability of pioglitazone. Exp. Clin. Endocrinol. Diab., 108: S267-S273. DOI: 10.1055/ s-2000-8529
23. Seufert, J. and R. Urquhart, 2008. 2-Year effects of pioglitazone add-on to sulphonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes. Diab. Res. Clin. Pract., 79: 453-460. DOI: 10.1016/ J.DIABRES.2007.11.014
24. Fujita, Y., Y. Yamada, M. Kusama, T. Yamauchi, J. Kamon, T Kadowaki and T. Iga, 2003. Sex differences in the pharmacokinetics of pioglitazone in rats. Comp. Biochem. Physiol. C Toxicol. Pharmacol., 136: 85-94. DOI: 10.1016/s1532-0456(03)00194-7
25. Machha, A., F.I. Achike, A.M. Mustafa and M.R. Mustafa, 2007. Quercetin, a flavonoid antioxidant, modulates endothelium-derived nitric oxide bioavailability in diabetic rat aortas. Nitric Oxide, 16: 442-447. DOI: 10.1016/j.niox.2007.04.001.
26. Friedenberg, F.K. and H.P. Parkman, 2006. Delayed gastric emptying: whom to test, how to test and what to do. Curr. Treat. Options Gastoenterol., 9: 295-304. http://www.ncbi.nlm.nih.gov/pubmed/16836948
27. Shakil, A., R.J. Church and S.S. Rao, 2008. Gastrointestinal complications of diabetes. Am. Fam. Phys., 77: 1697-1702. http://www.ncbi.nlm.nih.gov/pubmed/18619079